Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
524 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00992992 | Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody Plus CHOP For Untreated Mantle Cell Lymphoma | completed | Phase 2 | 25 | GlaxoSmithKlineINDUSTRY | 0 | Dec 4, 2019 | clinicaltrials |
| NCT01352286 | Redirected Auto T Cells for Advanced Myeloma | completed | Phase 2 | 25 | GlaxoSmithKlineINDUSTRY | 1 | Dec 3, 2019 | clinicaltrials |
| NCT00534638 |
| Effectiveness, Safety and Immunogenicity of GSK Biologicals' HPV Vaccine GSK580299 (Cervarix) Administered in Healthy Adolescents |
| completed |
| Phase 4 |
| 34,412 |
| GlaxoSmithKlineINDUSTRY |
| 1 |
| Nov 15, 2019 |
| clinicaltrials |
| NCT01249365 | The Safety Evaluation of the GSK-580299 Vaccine in Women From the Control Group in the Primary NCT00294047 Study | completed | Phase 3 | 199 | GlaxoSmithKlineINDUSTRY | 4 | Nov 13, 2019 | clinicaltrials |
| NCT01190176 | Gynaecological Follow-up of a Subset of HPV-015 (NCT00294047) Study Subjects | completed | Phase 3 | 34 | GlaxoSmithKlineINDUSTRY | 7 | Oct 30, 2019 | clinicaltrials |
| NCT00937950 | Gynaecological Follow-up of a Subset of 580299/008 (NCT00122681) Study Subjects | completed | Phase 3 | 2,022 | GlaxoSmithKlineINDUSTRY | 13 | Oct 29, 2019 | clinicaltrials |
| NCT01213472 | Evaluation of a New Anti-cancer Immunotherapy in Patients With Non-operable and Progressing Metastatic Cutaneous Melanoma | completed | Phase 1 | 33 | GlaxoSmithKlineINDUSTRY | 8 | Oct 9, 2019 | clinicaltrials |
| NCT02603172 | A Safety Study of GSK3039294 in Healthy Volunteers and Patients With Systemic Amyloidosis | terminated | Phase 1 | 23 | GlaxoSmithKlineINDUSTRY | 1 | Sep 23, 2019 | clinicaltrials |
| NCT03154086 | A Phase 1, First Time in Human (FTIH) Study to Evaluate GSK3352589, a REarranged During Transfection (RET) Growth Factor Receptor Tyrosine Kinase Inhibitor, in Healthy Volunteers | completed | Phase 1 | 68 | GlaxoSmithKlineINDUSTRY | 1 | Aug 9, 2019 | clinicaltrials |
| NCT01938443 | A Dose Escalation Study to Assess Safety of GSK2256098 (FAK Inhibitor) in Combination With Trametinib (MEK Inhibitor) in Subjects With Advanced Solid Tumors | completed | Phase 1 | 34 | GlaxoSmithKlineINDUSTRY | 2 | Jul 12, 2019 | clinicaltrials |
| NCT01966445 | Dose Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of GSK2849330 in Subjects With Advanced Her3-Positive Solid Tumors | completed | Phase 1 | 29 | GlaxoSmithKlineINDUSTRY | 3 | Jul 1, 2019 | clinicaltrials |
| NCT02177812 | A Phase I Dose Escalation Study of GSK2879552 in Subjects With Acute Myeloid Leukemia (AML) | terminated | Phase 1 | 41 | GlaxoSmithKlineINDUSTRY | 3 | Jun 28, 2019 | clinicaltrials |
| NCT00065182 | Comparison of IV Topotecan/Docetaxel to Docetaxel Alone in Second-Line Stage IIIB/IV Non-Small Cell Lung Cancer | completed | Phase 2 | 399 | GlaxoSmithKlineINDUSTRY | 3 | Jun 24, 2019 | clinicaltrials |
| NCT02000817 | Investigation of Otelixizumab in New-Onset, Autoimmune Type 1 Diabetes Mellitus Patients | completed | Phase 1 / Phase 2 | 30 | GlaxoSmithKlineINDUSTRY | 1 | Jun 24, 2019 | clinicaltrials |
| NCT00685750 | Expression Analysis of Specific Markers in Non-small Cell Lung Cancer or Melanoma | terminated | N/A | 88 | GlaxoSmithKlineINDUSTRY | 5 | Jun 20, 2019 | clinicaltrials |
| NCT01190189 | Safety Evaluation of the GSK-580299 Vaccine in Women From the Control Group in the Primary NCT00294047 Study | completed | Phase 3 | 137 | GlaxoSmithKlineINDUSTRY | 2 | Jun 19, 2019 | clinicaltrials |
| NCT00779766 | Efficacy, Immunogenicity and Safety of GSK Biologicals' HPV GSK 580299 Vaccine in Healthy Chinese Female Subjects | completed | Phase 3 | 6,081 | GlaxoSmithKlineINDUSTRY | 1 | Jun 10, 2019 | clinicaltrials |
| NCT00128661 | Vaccine To Prevent Cervical Intraepithelial Neoplasia or Cervical Cancer in Younger Healthy Participants | completed | Phase 3 | 7,466 | GlaxoSmithKlineINDUSTRY | 1 | Mar 8, 2019 | clinicaltrials |
| NCT02345174 | Immuno Positron Emission Tomography Study of GSK2849330 in Subjects With Human Epidermal Growth Factor Receptor 3-Positive Solid Tumors | completed | Phase 1 | 6 | GlaxoSmithKlineINDUSTRY | 1 | Feb 21, 2019 | clinicaltrials |
| NCT02314143 | Phase II Biomarker Study Comparing the Combination of BRAF Inhibitor Dabrafenib With MEK Inhibitor Trametinib Versus the Combination After Monotherapy With Dabrafenib or Trametinib | terminated | Phase 2 | 48 | GlaxoSmithKlineINDUSTRY | 2 | Feb 18, 2019 | clinicaltrials |
| NCT03336567 | Perceptions of Cell and Gene Therapies (CGT) for the Treatment of Cancer | completed | — | 40 | GlaxoSmithKlineINDUSTRY | 1 | Feb 5, 2019 | clinicaltrials |
| NCT00320411 | GW572016 In Patients With ErbB2 Over - Expressing Advanced Or Metastatic Breast Cancer | completed | Phase 2 | 62 | GlaxoSmithKlineINDUSTRY | 1 | Jan 31, 2019 | clinicaltrials |
| NCT01051063 | Evaluation of a New Anti-cancer Immunotherapy in Adult Acute Myeloid Leukemia Patients With a Suboptimal Clinical Response to Induction Chemotherapy | completed | Phase 1 | 17 | GlaxoSmithKlineINDUSTRY | 3 | Nov 29, 2018 | clinicaltrials |
| NCT00281632 | A Phase II, Open-Label Study Evaluating the Effect Of GW786034 In Subjects With Ovarian Cancer | completed | Phase 2 | 35 | GlaxoSmithKlineINDUSTRY | 3 | Sep 17, 2018 | clinicaltrials |
| NCT00309166 | Evaluation of the Immunogenicity and Safety of GlaxoSmithKline Biologicals' HPV Vaccine in Young Males. | completed | Phase 2 | 270 | GlaxoSmithKlineINDUSTRY | 1 | Sep 17, 2018 | clinicaltrials |
| NCT00477464 | Lapatinib in Combination With Capecitabine in Japanese Patients With Metastatic Breast Cancer | completed | Phase 2 | 51 | GlaxoSmithKlineINDUSTRY | 1 | Sep 17, 2018 | clinicaltrials |
| NCT01064349 | Breast Cancer With Over-expression of erbB2-BRAINSTORM | completed | — | 144 | GlaxoSmithKlineINDUSTRY | 3 | Sep 14, 2018 | clinicaltrials |
| NCT01357863 | Role of Early Versus Late Switch to Lapatinib-Capecitabine((TYCO1)) | terminated | — | 3 | GlaxoSmithKlineINDUSTRY | 1 | Sep 14, 2018 | clinicaltrials |
| NCT02447939 | Pharmacokinetics of Repeat Oral Doses of Dabrafenib and the Combination of Dabrafenib and Trametinib in Chinese Subjects With Melanoma | withdrawn | Phase 1 | 0 | GlaxoSmithKlineINDUSTRY | 0 | Sep 14, 2018 | clinicaltrials |
| NCT02939846 | Pharmacokinetics of Single and Repeat Oral Doses of Trametinib in Chinese Subjects With Solid Tumours | withdrawn | Phase 1 | 0 | GlaxoSmithKlineINDUSTRY | 0 | Sep 14, 2018 | clinicaltrials |
| NCT00316693 | Human Papillomavirus (HPV) Vaccine (Cervarix TM) Efficacy, Immunogenicity & Safety Trial in Adult Japanese Women With GSK Biologicals HPV-16/18 Vaccine | completed | Phase 2 | 1,046 | GlaxoSmithKlineINDUSTRY | 1 | Sep 4, 2018 | clinicaltrials |
| NCT00492544 | Immunogenicity and Safety of GSK Biologicals' HPV Vaccine 580299 in Healthy Japanese Females 10-15 Years of Age | completed | Phase 3 | 100 | GlaxoSmithKlineINDUSTRY | 1 | Sep 4, 2018 | clinicaltrials |
| NCT00371488 | GW572016 Combined With Trastuzumab For The Treatment Of Previously Trastuzumab-Treated Breast Cancer | completed | Phase 1 | 11 | GlaxoSmithKlineINDUSTRY | 1 | Aug 31, 2018 | clinicaltrials |
| NCT00462956 | GW572016 In Patients With Advanced Or Metastatic Breast Cancer | completed | Phase 1 | 59 | GlaxoSmithKlineINDUSTRY | 1 | Aug 31, 2018 | clinicaltrials |
| NCT00122681 | Human Papilloma Virus (HPV) Vaccine Efficacy Trial Against Cervical Pre-cancer in Young Adults With GlaxoSmithKline (GSK) Biologicals HPV-16/18 | completed | Phase 3 | 18,729 | GlaxoSmithKlineINDUSTRY | 14 | Aug 20, 2018 | clinicaltrials |
| NCT00541970 | Partially Blind Study to Evaluate Immunogenicity & Safety of GSK Bio's HPV Vaccine 580299 in Healthy Women Aged 9-25 Yrs | completed | Phase 1 | 961 | GlaxoSmithKlineINDUSTRY | 2 | Aug 17, 2018 | clinicaltrials |
| NCT00578227 | Evaluation of Safety and Immunogenicity of Co-administering Human Papillomavirus Vaccine With Another Vaccine in Healthy Female Subjects | completed | Phase 3 | 814 | GlaxoSmithKlineINDUSTRY | 4 | Aug 17, 2018 | clinicaltrials |
| NCT00652938 | Evaluation of Immunogenicity and Safety of Human Papillomavirus (HPV) Vaccine Co-administered With Another Vaccine in Healthy Female Subjects | completed | Phase 3 | 744 | GlaxoSmithKlineINDUSTRY | 2 | Aug 17, 2018 | clinicaltrials |
| NCT00996125 | Immunogenicity and Safety Study of GSK Biologicals' Human Papillomavirus 580299 Vaccine in Healthy Female Subjects | completed | Phase 3 | 750 | GlaxoSmithKlineINDUSTRY | 1 | Aug 17, 2018 | clinicaltrials |
| NCT01277042 | Study to Assess Immune Responses and Safety of the GSK-580299 Vaccine in Healthy Women (26 to 45 Years) | completed | Phase 3 | 1,212 | GlaxoSmithKlineINDUSTRY | 1 | Aug 17, 2018 | clinicaltrials |
| NCT01978236 | Dabrafenib/Trametinib, BRAF or BRAF AND MEK Pre-op With BRAF and MEK Post-op, Phase IIB, Melanoma With Brain Mets,Biomarkers and Metabolites | terminated | Phase 2 | 6 | GlaxoSmithKlineINDUSTRY | 2 | Aug 17, 2018 | clinicaltrials |
| NCT00725283 | Evaluation of a New Anti-cancer Immunotherapy After Chemotherapy in Adult Patients With Acute Myeloid Leukemia (AML) | completed | Phase 1 | 34 | GlaxoSmithKlineINDUSTRY | 2 | Aug 7, 2018 | clinicaltrials |
| NCT01706185 | Incidence of Expression of Tumor Antigens in Cancer Tissue From Patients With Pathologically Demonstrated Bladder Cancer | completed | — | 156 | GlaxoSmithKlineINDUSTRY | 1 | Jul 31, 2018 | clinicaltrials |
| NCT01290393 | Post-marketing Study to Assess the Safety of CERVARIX When Used in the United States and in Canada | terminated | — | 2 | GlaxoSmithKlineINDUSTRY | 1 | Jul 26, 2018 | clinicaltrials |
| NCT01458067 | A Phase I/IIa, First Time in Human, Study of GSK2636771 in Subjects With Advanced Solid Tumors With Phosphatase and Tensin Homolog (PTEN) Deficiency | completed | Phase 1 | 30 | GlaxoSmithKlineINDUSTRY | 3 | Jul 24, 2018 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials